TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. announced that its drug, Telitacicept, has successfully met the primary endpoint in Stage A of a Phase III clinical trial for treating IgA Nephropathy in China. This achievement marks a significant step forward for the company as it plans to submit a Biologics License Application to the National Medical Products Administration of China. The trial demonstrated a 55% reduction in the 24-hour urine protein-to-creatinine ratio, indicating the drug’s potential efficacy and safety. This development could position RemeGen as a key player in addressing the unmet medical need for novel IgAN therapeutics, potentially impacting the chronic kidney disease market.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a pharmaceutical company based in China, specializing in the development of innovative biologic drugs. The company focuses on creating treatments for autoimmune diseases and other serious health conditions, with a market emphasis on China.
Average Trading Volume: 11,432,554
Technical Sentiment Signal: Buy
Current Market Cap: HK$51.64B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.